MARKET

ELDN

ELDN

Eledon Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.50
-0.04
-0.24%
Closed 16:00 02/24 EST
OPEN
16.25
PREV CLOSE
16.54
HIGH
16.77
LOW
16.16
VOLUME
46.98K
TURNOVER
--
52 WEEK HIGH
27.32
52 WEEK LOW
4.500
MARKET CAP
236.06M
P/E (TTM)
-0.7329
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Eledon Pharmaceuticals to Present at 10th Annual SVB Leerink Global Healthcare Conference
Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons undergoing organ or cellular transplantation, as well as those living with immunological ...
GlobeNewswire · 02/17 13:00
DJ Eledon Pharmaceuticals Price Target Announced at $34.00/Share by SVB Leerink
Dow Jones · 02/08 13:32
DJ Eledon Pharmaceuticals Initiated at Outperform by SVB Leerink
Dow Jones · 02/08 13:32
--Analyst Actions: SVB Leerink Starts Eledon Pharmaceuticals at Outperform With $34 Price Target
MT Newswires · 02/08 09:01
Eledon Pharmaceuticals to Participate in the Virtual Noble Capital Markets' Seventeenth Annual Investor / Equity Conference
IRVINE, Calif., Jan 19, 2021 (GLOBE NEWSWIRE via COMTEX) -- IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon")...
GlobeNewswire · 01/19 22:55
Eledon Pharmaceuticals to Participate in the Virtual Noble Capital Markets' Seventeenth Annual Investor / Equity Conference
IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons undergoing organ or cellular transplant...
GlobeNewswire · 01/19 22:55
Eledon Pharmaceuticals to Participate in the Virtual Noble Capital Markets' Seventeenth Annual Investor / Equity Conference
IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons undergoing organ or cellular transplant...
GlobeNewswire · 01/19 22:55
Eledon Pharmaceuticals to Participate in the Virtual Noble Capital Markets' Seventeenth Annual Investor / Equity Conference
IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons undergoing organ or cellular transplant...
GlobeNewswire · 01/19 22:55
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ELDN. Analyze the recent business situations of Eledon Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ELDN stock price target is 34.75 with a high estimate of 43.00 and a low estimate of 27.00.
EPS
Institutional Holdings
Institutions: 44
Institutional Holdings: 6.45M
% Owned: 45.11%
Shares Outstanding: 14.31M
TypeInstitutionsShares
Increased
7
601.33K
New
15
4.75M
Decreased
6
3.73M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.18%
Pharmaceuticals & Medical Research
+1.08%
Key Executives
Chairman/Independent Director
Keith Katkin
President/Chief Scientific Officer
Steven Perrin
Chief Executive Officer/Director
David-Alexandre Gros
Chief Financial Officer/Chief Accounting Officer
Jon Kuwahara
Director
June Lee
Director
John McBride
Independent Director
Gary Lyons
Independent Director
Walter Ogier
  • Dividends
  • Splits
  • Insider Activity
No Data
About ELDN
Eledon Pharmaceuticals, Inc., formerly Novus Therapeutics, Inc., is a pharmaceutical company. The Company is focused on developing targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases. The Company’s lead product candidate, AT-1501, is a humanized monoclonal antibody (mAb), designed to target CD40 Ligand (CD40L), a molecule expressed on the surface of human immune system T cells. The central role of CD40/CD40L signaling in generating pro-inflammatory responses makes it an attractive candidate for therapeutic intervention in autoimmune disease, induction and maintenance of transplant tolerance, and neuroinflammation. Blocking the activation of the CD40L pathway ameliorates disease progression and pathology in preclinical models of autoimmunity and prevents acute and long-term allograft transplant rejection in multiple animal species.

Webull offers kinds of Eledon Pharmaceuticals Inc stock information, including NASDAQ:ELDN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELDN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ELDN stock methods without spending real money on the virtual paper trading platform.